Additional file 1 of Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy
Creators: name: Zhan, Meixiao
name: Yu, Xiangrong
name: Zhao, Wei
name: Peng, Yongjun
name: Peng, Shaojun
name: Li, Jingchao
name: Lu, Ligong
Publisher: name: figshare
Year: 2022
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1: Fig. S1. TGA analysis of FeS2, BSA-FeS2, NA0, NAc and dNAc. Fig. S2. Photographs of aqueous solutions of NA0, NAc and dNAc after storage for 2 weeks. Fig. S3. (a) Photographs of red blood cells after treatments with 1% Triton X-100 (+ control), PBS buffer (− control), and NA0, NAc or dNAc at different concentrations (7.5, 15, 30, 60, and 120 μg/mL) for 2 h. (b) Hemolysis assay of red blood cells after treatments with NA0, NAc or dNAc at different concentrations for 2 h. Fig. S4. Thermal imaging of NA0, NAc and dNAc as a foundation of laser irradiation time under NIR-II laser irradiation at the power density of 1 W/cm2. Fig. S5. (a) Thermal imaging of dNAc solutions covered with chicken breast tissue of different thicknesses (0, 1, 3, 5, and, 7 mm) as a foundation of laser irradiation time under NIR-II laser irradiation at the power density of 1 W/cm2. (b) Temperature curves of dNAc covered with chicken breast tissue of different thicknesses (0, 1, 3, 5, and 7 mm) after treatment of NIR-II laser (1 W/cm2) for different time. (c) Temperature increment (ΔT) of dNAc covered with chicken breast tissue of different thicknesses (0, 1, 3, 5, and 7 mm) after treatment of NIR-II laser (1 W/cm2) for different time. Fig. S6. Cell viability of 4T1 cancer cells after incubation with NA0, NAc or dNAc at different concentrations (0, 20, 40, 60, 80, and 100 μg/mL) for 24 h. Fig. S7. Confocal fluorescence images of 4T1 cancer cells after treatment with PBS, NA0, NAc and dNAc (50 μg/mL) in the absence of H2O2. Fig. S8. Prussian blue staining images of tumor sections from 4T1 tumor-bearing mice after intravenous injection of saline, NA0, NAc and dNAc at 6 h post-injection timepoint. Black arrow indicated Prussian blue staining of Fe. Fig. S9. H&amp;E staining images of primary tumors (a) and distant tumors (b) from 4T1 tumor-bearing mice after intravenous injection of NA0, NAc and dNAc with or without NIR-II laser irradiation. Fig. S10. TUNEL staining images of primary tumors (a) and distant tumors (b) from 4T1 tumor-bearing mice after intravenous injection of NA0, NAc and dNAc with or without NIR-II laser irradiation. Fig. S11. Ki67 staining images of primary tumors (a) and distant tumors (b) from 4T1 tumor-bearing mice after intravenous injection of NA0, NAc and dNAc with or without NIR-II laser irradiation. Fig. S12. Flow cytometry assay of CD3+CD4+ T cells in primary tumors (a) and distant tumors (b) of mice after intravenous injection of nanoagonists with or without NIR-II laser irradiation. Fig. S13. Flow cytometry assay of CD3+CD8+ T cells in primary tumors (a) and distant tumors (b) of mice after intravenous injection of nanoagonists with or without NIR-II laser irradiation. Fig. S14. H&amp;E staining images of heart, liver, spleen, lung, and kidney of mice after intravenous injection of BSA-FeS2 nanoparticles. Fig. S15. The serum levels of (a) alkaline phosphatase (ALP), (b) alanine aminotransferase (ALT), (c) aspartate aminotransferase (AST), (d) blood urea nitrogen (BUN) and (e) creatinine (CREA) in mice after intravenous injection of BSA-FeS2 nanoparticles. Fig. S16. Biodistribution of BSA-FeS2 nanoparticles in heart, liver, spleen, lung, kidney, and tumors at different post-injection timepoints. Fig. S17. Body weight of 4T1 tumor-bearing mice after intravenous injection of NA0, NAc or dNAc with or without NIR-II laser irradiation for different days. Fig. S18. H&amp;E staining images of heart, spleen, and kidney of mice after different treatments for 21 days. Fig. S19. The level of (a) red blood cells, (b) red cell distribution width, (c) white blood cells, (d) mean corpuscular hemoglobin, (e) mean corpuscular volume, (f) hematocrit, (g) hemoglobin, (h) ALP, (i) ALT, (j) AST, (k) BUN and (l) CREA in blood samples of control mice and mice after dNAc-mediated therapy.